BioRx Program Demonstrates Significant Reductions in Parenteral Nutrition Utilization and Costs
Cincinnati, Ohio (November 18, 2014) — ThriveRx, a unit of BioRx, announced the results of a study evaluating the impact of its Maximize Health! program in reducing parenteral nutrition (PN) requirements for patients being treated for short bowel syndrome (SBS). During its Professional Short Bowel Conference in Nashville, Tenn., November 5 to 6, ThriveRx showed that patients enrolled in its Maximize Health! program were able to reduce their weekly PN intake by 28% on average – 5.3 times more than those not enrolled (3,825 mL per week vs. 725 mL).
“Parenteral nutrition therapy can cost between $60,000 to $150,000 or more per year, depending on the complexity of the case,” said Eric Hill, co-founder of BioRx. “This study shows that our Maximize Health program completely eliminated the need for parenteral nutrition and its associated costs for a full 25% of the patient population and, overall, reduced average PN therapy costs by 28%.”
Clinical studies in controlled, institutional settings have shown that an intestinal rehabilitation (IR) approach to nutrition support can significantly reduce the need for routine use of PN therapy and intravenous fluids in SBS patients. Maximize Health! is the first nutrition support program to follow a similar IR approach in the home setting. To evaluate the real-world application of an IR model for SBS at home, ThriveRx conducted a retrospective review of PN volume requirements of 37 SBS patients who were either enrolled (n=12) or not enrolled (25) in the Maximize Health! program.
In addition to demonstrating a greater reduction in PN volume, Maximize Health! enrollees showed a greater likelihood of weaning from PN therapy altogether – 25% for patients enrolled vs. 8% for those not enrolled. Overall, 58% of Maximize Health! enrollees were able to wean or reduce their PN intake, while another 25% remained unchanged. On average, program enrollees were able to reduce their PN intake by 28% (vs. 5% for those not enrolled).
“These results show that an intestinal rehabilitation approach to nutrition therapy can, and does, work in the home setting,” said Deb Pfister, RD, CNSD, director of nutrition services at ThriveRx. “Safely reducing PN intake has inherent benefits to a patient’s health and quality of life, but it can also dramatically reduce annual healthcare expenditures.”
The Maximize Health! program includes a team of dietitians, nurses, pharmacists and clinical coordinators. Together, they provide a range of interventions aimed at optimizing the absorption of nutrients from PN therapy. This includes diet education based on a patient’s individual bowel anatomy, optimization of fluid and electrolyte balance, counseling on medication management of GI output, management of vitamin and mineral deficiencies, assessment of bone and liver health, and ongoing, routine monitoring.
Download news release (PDF)
About Short Bowel Syndrome
SBS is a condition that generally occurs due to the removal of a large segment of the small intestine during surgery (“resection”). SBS results when the remaining part of the small intestine cannot absorb enough nutrients and fluids from food to maintain good health. SBS can also be caused by disease or injury that prevents the small intestine from functioning properly despite a normal length.
ThriveRx, a specialty service unit of BioRx, provides highly customized care for individuals with chronic nutritional deficiencies who require intravenous nutrition and tube feeding. To learn more, visit www.thriverx.net.
BioRx is a highly specialized pharmacy and infusion services provider that secures necessary treatments for patients with ultra-orphan and rare, chronic diseases. In addition to pharmacy and infusion services, BioRx also serves health plans and payer organizations with comprehensive data analytics and outcomes reporting – at the member-specific and population-wide levels. The company’s clinical staff reaches patients in all 50 states and operates dispensing facilities in Ohio, Massachusetts, North Carolina, Iowa, Minnesota, Arizona and California. To learn more, visit www.biorx.com.